• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

• Catalysts and Inorganic Chemicals Inorganic Compounds Homogeneous non-metal compounds Homogeneous other non-metal compounds

Recent Advances in the Application of Bicyclo[1.1.1]pentane-1,3-dicarbonitrile (CAS: 97460-11-2) in Chemical Biology and Pharmaceutical Research

Bicyclo[1.1.1]pentane-1,3-dicarbonitrile (CAS: 97460-11-2) has emerged as a versatile scaffold in chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery. This compound, characterized by its strained bicyclic framework and dual nitrile functionalities, has garnered significant attention for its ability to serve as a bioisostere for aromatic rings and other rigid structures. Recent studies have explored its utility in enhancing the pharmacokinetic properties of drug candidates, particularly in improving metabolic stability and membrane permeability.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the successful incorporation of Bicyclo[1.1.1]pentane-1,3-dicarbonitrile into protease inhibitors, resulting in compounds with improved potency and selectivity. The researchers utilized computational modeling to predict the optimal positioning of the scaffold within the active site, followed by synthetic modification to validate these predictions. The resulting analogs showed a 3- to 5-fold increase in binding affinity compared to their aromatic counterparts, while maintaining favorable ADME (Absorption, Distribution, Metabolism, and Excretion) profiles.

In parallel, advancements in synthetic methodologies have facilitated the broader application of this scaffold. A recent Nature Communications article (2024) described a novel photocatalytic protocol for the late-stage functionalization of Bicyclo[1.1.1]pentane-1,3-dicarbonitrile, enabling the rapid generation of diverse derivatives for structure-activity relationship studies. This development has significantly expanded the chemical space accessible for medicinal chemistry optimization campaigns targeting challenging biological targets.

The unique three-dimensional structure of Bicyclo[1.1.1]pentane-1,3-dicarbonitrile has also found applications in chemical biology probes. Researchers have exploited its rigid geometry to design conformationally constrained inhibitors of protein-protein interactions, particularly in the field of oncology. A recent ACS Chemical Biology publication highlighted its use in developing selective inhibitors of the MDM2-p53 interaction, with the scaffold effectively mimicking key hydrophobic residues while maintaining solubility properties unattainable with traditional aromatic systems.

Ongoing research continues to uncover new dimensions of this scaffold's utility. Current investigations focus on its potential in CNS drug development, where its ability to cross the blood-brain barrier while resisting metabolic degradation offers distinct advantages. Preliminary results from these studies suggest that Bicyclo[1.1.1]pentane-1,3-dicarbonitrile derivatives may provide solutions to longstanding challenges in neuropharmacology, particularly in the treatment of neurodegenerative diseases.

As the field progresses, the integration of Bicyclo[1.1.1]pentane-1,3-dicarbonitrile into drug discovery pipelines is expected to accelerate, driven by both its demonstrated benefits and the development of more efficient synthetic routes. The compound's unique combination of structural features and functional group compatibility positions it as a valuable tool for addressing complex medicinal chemistry challenges in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)